Literature DB >> 23563890

Treating hypertension in patients with left ventricular dysfunction: hitting the fairway and avoiding the rough.

Samuel W Joffe1, Robert A Phillips.   

Abstract

Hypertension is a major risk factor in the development of heart failure (HF), yet current guidelines do not specify a target blood pressure (BP) for patients with established systolic or diastolic left ventricular (LV) dysfunction. While no randomized controlled trial (RCT) has been conducted to specify the optimal blood pressure in these patients, numerous trials have demonstrated the benefits of certain classes of medications and treatment strategies in patients with HF. Important factors to consider in treating hypertension in patients with HF include the type of HF (reduced vs. preserved ejection fraction), the etiology (ischemic vs. nonischemic), the severity of symptoms if any, the baseline blood pressure, as well as a wide variety of patient-specific factors. This paper reviews current evidence to address the question, "What should be the blood pressure goal in patients with asymptomatic and symptomatic left ventricular dysfunction?" We suggest a target blood pressure of 120-140/70-90 mm Hg in most cases, with lower pressures generally preferable if tolerated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23563890     DOI: 10.1007/s11897-013-0137-9

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  48 in total

1.  Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.

Authors:  S Hinan Ahmed; Leslie L Clark; Weems R Pennington; Carson S Webb; D Dirk Bonnema; Amy H Leonardi; Catherine D McClure; Francis G Spinale; Michael R Zile
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

2.  Hypertensive vascular disease; description and natural history.

Authors:  G A PERERA
Journal:  J Chronic Dis       Date:  1955-01

3.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

4.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  Prehypertension and cardiovascular disease risk in the Women's Health Initiative.

Authors:  Judith Hsia; Karen L Margolis; Charles B Eaton; Nanette K Wenger; Matthew Allison; LieLing Wu; Andrea Z LaCroix; Henry R Black
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

7.  One-year mortality among unselected outpatients with heart failure.

Authors:  J Muntwyler; G Abetel; C Gruner; F Follath
Journal:  Eur Heart J       Date:  2002-12       Impact factor: 29.983

8.  Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.

Authors:  Scott D Solomon; Rajesh Janardhanan; Anil Verma; Mikhail Bourgoun; William L Daley; Das Purkayastha; Yves Lacourcière; Stephen E Hippler; Harold Fields; Tasneem Z Naqvi; Sharon L Mulvagh; J Malcolm O Arnold; James D Thomas; Michael R Zile; Gerard P Aurigemma
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.

Authors:  R A P Weir; John J V McMurray; Margareta Puu; Scott D Solomon; Bertil Olofsson; Christopher B Granger; Salim Yusuf; Eric L Michelson; Karl Swedberg; Marc A Pfeffer
Journal:  Eur J Heart Fail       Date:  2008-01-31       Impact factor: 15.534

View more
  1 in total

1.  Antihypertensive medications and diastolic dysfunction progression in an African American population.

Authors:  Heather M Prendergast; Samuel Dudley; Michael Brown; Martha Daviglus; John Kane; E Bradshaw Bunney; Jared Marcucci; Rasheed Sanyaolu
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.